# Yuanyuan Zhao

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/yuanyuan-zhao/

## Facts

| Field | Value |
| --- | --- |
| Citations | 6,303 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 42 |
| i10-index | 109 |
| Last Known Institution | Sun Yat-sen University |
| OpenAlex ID | https://openalex.org/A5020252828 |
| ORCID iD | 0000-0002-7148-7608 |
| Works | 268 |

## Researcher papers

- [Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials](https://scholariq.org/papers/camrelizumab-shr-1210-alone-or-in-combination-with-gemcitabine-plus-cisplatin/)
- [EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy](https://scholariq.org/papers/ebv-driven-lmp1-and-ifn-up-regulate-pd-l1-in-nasopharyngeal-carcinoma/)
- [Genomic Analysis of Nasopharyngeal Carcinoma Reveals TME-Based Subtypes](https://scholariq.org/papers/genomic-analysis-of-nasopharyngeal-carcinoma-reveals-tme-based-subtypes/)
- [Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)](https://scholariq.org/papers/tislelizumab-plus-chemotherapy-as-first-line-treatment-for-recurrent-or/)
- [Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With <i>EGFR</i> Variant](https://scholariq.org/papers/ivonescimab-plus-chemotherapy-in-non-small-cell-lung-cancer-with-i-egfr-i/)
- [Ratio of C-Reactive Protein/Albumin is An Inflammatory Prognostic Score for Predicting Overall Survival of Patients with Small-cell Lung Cancer](https://scholariq.org/papers/ratio-of-c-reactive-protein-albumin-is-an-inflammatory-prognostic-score-for/)
- [Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma](https://scholariq.org/papers/co-expression-of-pd-1-and-pd-l1-predicts-poor-outcome-in-nasopharyngeal/)
- [Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients](https://scholariq.org/papers/upregulation-of-pd-l1-by-eml4-alk-fusion-protein-mediates-the-immune-escape-in/)
- [Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations](https://scholariq.org/papers/network-meta-analysis-of-erlotinib-gefitinib-afatinib-and-icotinib-in-patients/)
- [The genomic landscape of Epstein-Barr virus-associated pulmonary lymphoepithelioma-like carcinoma](https://scholariq.org/papers/the-genomic-landscape-of-epstein-barr-virus-associated-pulmonary/)
- [Re-biopsy confers survival benefit through directing salvage treatment for patients failing prior EGFR-TKIs](https://scholariq.org/papers/re-biopsy-confers-survival-benefit-through-directing-salvage-treatment-for/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)

## Researcher university

- [Sun Yat-sen University](https://scholariq.org/institutions/sun-yat-sen-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.